Newsroom | 66324 results

GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany, the findings represent one...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum to Host Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103), an investigational, potentially first-in-class tetravalent, tri-specific antibody designed to activate the Wingless-related integration site (Wnt) pathway, for the treatment of diabetic macular edema (DME). Results were presented today at the...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational vamikibart compared with a sham procedure that mimics intravitreal (IVT) injections in adults with uveitic macular edema (UME). Across both studies, data continue to support the potential for rapid and sustained improvements in vision and reductions in macular thickness (swel...

DAVIS, Calif.--(BUSINESS WIRE)--BioConsortia Receives $15 Million in New Funding for New Microbial Product Launches for Sustainable Agriculture....

ANN ARBOR, Mich.--(BUSINESS WIRE)--Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced the presentation of efficacy, safety and new durability results from its Phase 2b/3 LIDS trial of linsitinib in adults with moderate to severe active TED. The data were highlighted in an oral presentation and in a poster session at the American Society of Ophthalmic Plastic and...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversib...

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress...

SAN ANTONIO--(BUSINESS WIRE)--BIAF announces closing of $4 million registered direct financing of common stock and private placement priced at-the-market under Nasdaq rules...

ليكسينغتون، ماساتشوستس--(BUSINESS WIRE)--أعلنت Agenus Inc. (المدرجة في بورصة ناسداك بالرمز: AGEN)، الشركة الرائدة في مجال ابتكار العلاجات المناعية للسرطان، اليوم أن وزارة الصحة في جمهورية أرمينيا منحت تراخيص تسويق لكلٍّ من Botvymo® (botensilimab، BOT) وEvamplix® (balstilimab، BAL)، حيث تمت الموافقة على استخدام كل منهما بالاشتراك مع الآخر لعلاج المرضى البالغين المصابين بسرطان القولون والمستقيم النقيلي المستقر ميكروساتليًا (MSS)، الذين لا يعانون من نقائل نشطة في الكبد، وسبق أن تلقوا العلاجات القيا...